JP7320282B2 - 異常ｔｄｐ－４３を分解除去する抗体断片 - Google Patents

異常ｔｄｐ－４３を分解除去する抗体断片 Download PDF

Info

Publication number
JP7320282B2
JP7320282B2 JP2020506667A JP2020506667A JP7320282B2 JP 7320282 B2 JP7320282 B2 JP 7320282B2 JP 2020506667 A JP2020506667 A JP 2020506667A JP 2020506667 A JP2020506667 A JP 2020506667A JP 7320282 B2 JP7320282 B2 JP 7320282B2
Authority
JP
Japan
Prior art keywords
tdp
antibody fragment
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020506667A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019177138A5 (https=
JPWO2019177138A1 (ja
Inventor
真 漆谷
良高 玉木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiga University of Medical Science NUC
Original Assignee
Shiga University of Medical Science NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiga University of Medical Science NUC filed Critical Shiga University of Medical Science NUC
Publication of JPWO2019177138A1 publication Critical patent/JPWO2019177138A1/ja
Publication of JPWO2019177138A5 publication Critical patent/JPWO2019177138A5/ja
Application granted granted Critical
Publication of JP7320282B2 publication Critical patent/JP7320282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020506667A 2018-03-16 2019-03-15 異常ｔｄｐ－４３を分解除去する抗体断片 Active JP7320282B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018049752 2018-03-16
JP2018049752 2018-03-16
PCT/JP2019/010771 WO2019177138A1 (ja) 2018-03-16 2019-03-15 異常ｔｄｐ－４３を分解除去する抗体断片

Publications (3)

Publication Number Publication Date
JPWO2019177138A1 JPWO2019177138A1 (ja) 2021-05-13
JPWO2019177138A5 JPWO2019177138A5 (https=) 2022-02-24
JP7320282B2 true JP7320282B2 (ja) 2023-08-03

Family

ID=67906698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020506667A Active JP7320282B2 (ja) 2018-03-16 2019-03-15 異常ｔｄｐ－４３を分解除去する抗体断片

Country Status (5)

Country Link
US (1) US12215142B2 (https=)
EP (1) EP3770262B1 (https=)
JP (1) JP7320282B2 (https=)
CN (1) CN112236523A (https=)
WO (1) WO2019177138A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222168A2 (en) 2020-04-28 2021-11-04 Sola Biosciences Llc Compositions and methods for the treatment of tdp-43 proteinopathies
WO2022163438A1 (ja) * 2021-01-26 2022-08-04 株式会社ニコン 神経細胞の解析方法、神経細胞の解析装置およびコンピュータプログラム
US20250258180A1 (en) 2021-07-27 2025-08-14 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same
WO2023204313A1 (ja) 2022-04-22 2023-10-26 国立大学法人新潟大学 Ｔｄｐ－４３の凝集抑制剤及び医薬組成物
CN115894690B (zh) * 2022-11-30 2025-06-13 浙江大学 一种抗体降解子及其应用
CN116410311B (zh) * 2023-03-22 2023-12-12 暨南大学 胞内抗体及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008529A1 (ja) 2007-07-06 2009-01-15 Tokyo Metropolitan Organization For Medical Research Ｔｄｐ－４３凝集物に特異的に結合する抗体
JP2013162772A (ja) 2012-02-13 2013-08-22 Shiga Univ Of Medical Science Ｔｄｐ−４３の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬
JP2014171425A (ja) 2013-03-08 2014-09-22 Shiga Univ Of Medical Science Ｔｄｐ−４３の凝集体が蓄積する疾患を治療及び／又は予防するための化合物のスクリーニング方法
JP2015505665A (ja) 2011-10-28 2015-02-26 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
WO2016053610A1 (en) 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
RU2693661C2 (ru) 2016-03-04 2019-07-03 Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. Антитело против pdl-1, его фармацевтическая композиция и применение

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008529A1 (ja) 2007-07-06 2009-01-15 Tokyo Metropolitan Organization For Medical Research Ｔｄｐ－４３凝集物に特異的に結合する抗体
JP2015505665A (ja) 2011-10-28 2015-02-26 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー Ｔｄｐ−４３に特異的な結合分子
JP2013162772A (ja) 2012-02-13 2013-08-22 Shiga Univ Of Medical Science Ｔｄｐ−４３の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬
JP2014171425A (ja) 2013-03-08 2014-09-22 Shiga Univ Of Medical Science Ｔｄｐ−４３の凝集体が蓄積する疾患を治療及び／又は予防するための化合物のスクリーニング方法
WO2016053610A1 (en) 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMAKI, Y. et al.，Journal of the Neurological Sciences，2017年，Vol. 381，pp. 715, Abstract No. 1984

Also Published As

Publication number Publication date
EP3770262A4 (en) 2021-12-15
EP3770262A1 (en) 2021-01-27
US20210024621A1 (en) 2021-01-28
JPWO2019177138A1 (ja) 2021-05-13
WO2019177138A1 (ja) 2019-09-19
US12215142B2 (en) 2025-02-04
EP3770262B1 (en) 2026-01-14
CN112236523A (zh) 2021-01-15

Similar Documents

Publication Publication Date Title
JP7320282B2 (ja) 異常ｔｄｐ－４３を分解除去する抗体断片
Jairaman et al. TREM2 regulates purinergic receptor-mediated calcium signaling and motility in human iPSC-derived microglia
Adolfsson et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ
Langness et al. Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerization
Boscia et al. The expression and activity of KV3. 4 channel subunits are precociously upregulated in astrocytes exposed to Aβ oligomers and in astrocytes of Alzheimer's disease Tg2576 mice
EP2039367B1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
Zapata et al. Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission
JP2006508072A (ja) アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
CN113164508A (zh) 与神经保护剂组合的sarm1抑制剂
US12496360B2 (en) Gene editing-based method of attenuating the beta-amyloid pathway
Pignataro et al. Activity-induced amyloid-β oligomers drive compensatory synaptic rearrangements in brain circuits controlling memory of presymptomatic Alzheimer's disease mice
US20110224133A1 (en) Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases
US11236147B2 (en) Methods and compositions for the inhibition of TRPV4
TW201121570A (en) A method of promoting dendritic spine density
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
KR20260041670A (ko) 신규 퇴행성 신경질환 치료용 약학적 조성물
KR102187148B1 (ko) 산발적 파킨슨병 진단의 정보제공방법 및 약물 스크리닝 방법
Levy et al. Gtf2i-encoded transcription factor Tfii-i regulates myelination via Sox10 and Mbp regulatory elements
US20030219720A1 (en) Methods for identifying inhibitors of neuronal degeneration
WO2026056131A1 (en) Use of trpm7 activator in preparation of therapeutic product for treating alzheimer's disease
US20070275887A1 (en) Method of Inhibiting Secretase Activity
RU2812207C2 (ru) Способы и фармацевтические композиции для лечения заболеваний, связанных с тубулин карбоксипептидазами (tcp)
Tracy A novel postsynaptic location for Kv7 channels and their role in memory and nanoparticle advancement for dementia therapeutics
CN106619595A (zh) 包含2,5‑二羟基苯磺酸的用于促进神经细胞中髓鞘再生的组合物及其用途
EP4056696A1 (en) Synthetic alpha-secretase and use thereof

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20200626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230714

R150 Certificate of patent or registration of utility model

Ref document number: 7320282

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150